Tampa, United States
Nilogen Oncosystems differentiates itself by using proprietary preclinical drug testing platforms that utilize fresh patient tumor samples with intact tumor immune microenvironment. This approach provides a comprehensive understanding of the molecular mechanisms of drug sensitivity and resistance, offering a more complete picture for drug development. This methodology aims to reduce the cost and risk associated with clinical trials, ultimately benefiting the entire drug development process.
Nilogen Oncosystems' commitment to customizing cancer drug development has yielded remarkable results for its clients. While specific investment details are not currently available, the company's dedication to innovation and its proven track record make it an intriguing prospect for potential venture capital investment.
